User:Mr. Ibrahem/Anti-thymocyte globulin
Clinical data | |
---|---|
Trade names | Atgam, Thymoglobulin |
AHFS/Drugs.com | Horse: Monograph Rabbit: Monograph |
Routes of administration | Intravenous |
Drug class | Polyclonal antibody[1][2] |
(what is this?) (verify) |
Anti-thymocyte globulin (ATG), sold under the brand name Atgam and Thymoglobulin among others, are medication used to prevent and treat acute rejection follow an organ transplant.[1][2] Other uses may include myelodysplastic syndrome and aplastic anemia.[1] It is given by injection into a vein.[1]
Common side effects include fever, low white blood cells, low platelets, headache, nausea, serum sickness, and rash.[2] Other side effects may include anaphylaxis and infection.[2] Safety in pregnancy is unclear.[2] They are polyclonal antibody against thymocytes, derived from either horses or rabbits.[1][2] They are believed to work by altering the activity of T cells.[1][2]
Anti-thymocyte globulin was approved for medical use in the United States in 1981 for the horse version and 1998 for the rabbit version.[3][4] In the United Kingdom a 25 mg vial of the rabbit version costs the NHS about £160 as of 2021.[5] This amount in the United States costs about 800 USD.[6]
References[edit]
- ^ a b c d e f g "Antithymocyte Globulin (Rabbit) Monograph for Professionals". Drugs.com. Archived from the original on 13 August 2020. Retrieved 14 January 2022.
- ^ a b c d e f g h i "Antithymocyte Globulin (Equine) Monograph for Professionals". Drugs.com. Archived from the original on 20 August 2016. Retrieved 14 January 2022.
- ^ "DailyMed - ATGAM- equine thymocyte immune globulin injection, solution". dailymed.nlm.nih.gov. Archived from the original on 27 March 2021. Retrieved 14 January 2022.
- ^ "DailyMed - THYMOGLOBULIN (anti-thymocyte globulin- rabbit injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 20 March 2021. Retrieved 14 January 2022.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 882. ISBN 978-0857114105.
- ^ James, A; Mannon, RB (1 June 2015). "The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable?". Current transplantation reports. 2 (2): 113–121. doi:10.1007/s40472-015-0052-y. PMID 26236578.